1. Home
  2. YHGJ vs NEUP Comparison

YHGJ vs NEUP Comparison

Compare YHGJ & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yunhong Green CTI Ltd.

YHGJ

Yunhong Green CTI Ltd.

HOLD

Current Price

$3.49

Market Cap

11.2M

Sector

Industrials

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.88

Market Cap

10.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
YHGJ
NEUP
Founded
1975
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
10.3M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
YHGJ
NEUP
Price
$3.49
$3.88
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
19.4K
83.5K
Earning Date
11-13-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,377,000.00
$15,649,448.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.41
N/A
52 Week Low
$3.37
$2.90
52 Week High
$12.70
$21.40

Technical Indicators

Market Signals
Indicator
YHGJ
NEUP
Relative Strength Index (RSI) 31.79 40.68
Support Level $3.37 $3.65
Resistance Level $3.99 $3.91
Average True Range (ATR) 0.34 0.20
MACD -0.08 0.10
Stochastic Oscillator 11.65 50.48

Price Performance

Historical Comparison
YHGJ
NEUP

About YHGJ Yunhong Green CTI Ltd.

Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: